Obese and overweight men who are diagnosed with prostate cancer by biopsy are more likely than healthy weight men to actually have a more aggressive case of the disease than the biopsy results would indicate, according to a study led by a Duke University Medical Center researcher.
Chemists and biologists at Virginia Tech continuing to design light-activated molecular systems to attack cancer cells have introduced a DNA targeting component.
If you want the best technology available to relieve blocked blood flow to the heart, the choice is a drug-eluting stent. And you are most likely to obtain the drug-eluting stent for reasons that have nothing to do with your medical condition, a new Mayo Clinic study shows.
In an era of increasing death and illness from heart and blood vessel disease — which also can impair kidney function — Mayo Clinic researchers have designed two promising new cardiovascular treatment approaches.
An herbal medicinal substance, Crataegus Extract WS?1442, safely extends the lives of congestive heart failure patients already receiving pharmacological treatment for the disease, according to a study presented today at the American College of Cardiology?s 56th Annual Scientific Session.
Researchers today reported that an investigational anti-hypertensive therapy may perform better in controlling blood pressure than standard treatments for patients undergoing heart surgery, during a presentation at the American College of Cardiology?s 56th Annual Scientific Session.
Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
The costs due to complications from preterm birth are staggering. In Canada, outlays for specialized care of surviving preterm infants are estimated to be almost $2 billion per year.
For the first time, researchers have used adult bone marrow stem cells to regenerate healthy human liver tissue, according to a study published in the April issue of the journal Radiology.
Schering-Plough Corporation (NYSE: SGP) announced that it has entered into an agreement with Merck & Co., Inc. to commence development of an ezetimibe and atorvastatin combination product.